News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,918 Results
Type
Article (14919)
Company Profile (299)
Press Release (266694)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79850)
Career Advice (163)
Deals (13337)
Drug Delivery (39)
Drug Development (50707)
Employer Resources (31)
FDA (5840)
Job Trends (5169)
News (145105)
Policy (10073)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (20)
Adcomms (14)
Allergies (85)
Alliances (21762)
ALS (126)
Alzheimer's disease (1035)
Antibody-drug conjugate (ADC) (244)
Approvals (6036)
Artificial intelligence (267)
Autoimmune disease (119)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (101)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (348)
Cancer (3163)
Cardiovascular disease (239)
Career advice (148)
Career pathing (8)
CAR-T (224)
CDC (5)
Cell therapy (577)
Cervical cancer (14)
Clinical research (43724)
Collaboration (1168)
Company closure (2)
Compensation (604)
Complete response letters (42)
COVID-19 (1101)
CRISPR (88)
C-suite (566)
Cystic fibrosis (112)
Data (4359)
Denatured (15)
Depression (93)
Diabetes (257)
Diagnostics (1383)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (196)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31688)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51714)
Executive appointments (629)
FDA (7608)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (994)
Gene editing (185)
Generative AI (22)
Gene therapy (498)
GLP-1 (507)
Government (1150)
Grass and pollen (3)
Guidances (166)
Healthcare (6612)
HIV (18)
Huntington's disease (43)
IgA nephropathy (75)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (71)
Infectious disease (1211)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7346)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (244)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (425)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (380)
MASH (132)
Medical device (2672)
Medtech (2681)
Mergers & acquisitions (6623)
Metabolic disorders (734)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1966)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (31)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (165)
Parkinson's disease (233)
Partnered (12)
Patents (306)
Patient recruitment (345)
Peanut (44)
People (26696)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15493)
Phase 2 (20315)
Phase 3 (12831)
Pipeline (3355)
Policy (91)
Postmarket research (853)
Preclinical (6541)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (661)
Real estate (1449)
Recruiting (12)
Regulatory (9925)
Reports (19)
Research institute (973)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (184)
Series B (141)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (341)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (8)
Last 7 days (310)
Last 30 days (1110)
Last 365 days (17763)
2026 (1974)
2025 (18099)
2024 (20546)
2023 (22419)
2022 (26827)
2021 (27809)
2020 (23356)
2019 (16225)
2018 (11738)
2017 (13747)
2016 (11843)
2015 (14349)
2014 (10392)
2013 (7485)
2012 (7537)
2011 (7614)
2010 (7429)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18274)
Australia (3114)
California (7144)
Canada (1858)
China (784)
Colorado (249)
Connecticut (255)
Delaware (237)
Europe (39222)
Florida (913)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (398)
India (36)
Indiana (162)
Iowa (8)
Japan (228)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (740)
Massachusetts (5631)
Michigan (110)
Minnesota (250)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1658)
New Mexico (13)
New York (1776)
North Carolina (837)
North Dakota (6)
Northern California (3518)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2832)
Tennessee (40)
Texas (921)
United States (23543)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (46)
281,918 Results for "verve therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene editing
Verve’s Base Editor ‘Numerically Beats’ Other Cholesterol-Lowering Drugs
In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli Lilly and a showdown with Novartis.
April 14, 2025
·
2 min read
·
Dan Samorodnitsky
Gene editing
‘Safer’ CRISPR: Base Editing Breaks Through in the Clinic as Beam, Verve Advance
Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative to conventional CRISPR. Clinical results have so far been promising.
May 5, 2025
·
9 min read
·
Shawna Williams
Press Releases
Lilly and Verve announce expiration of Verve tender offer
July 25, 2025
·
5 min read
Press Releases
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
July 25, 2025
·
3 min read
Press Releases
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
June 17, 2025
·
12 min read
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing than normal” given the regulatory turmoil it revealed.
June 26, 2025
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Lilly Validates Gene Editing Space With $1.3B Verve Buy, But Analysts Are Skeptical
The pending deal was rumored overnight after a report from the
Financial Times
, spurring analysts to speculate that if true, the entire gene editing space would see a boost at the markets.
June 17, 2025
·
3 min read
·
Annalee Armstrong
Metabolic disorders
Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases
Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.
November 10, 2025
·
2 min read
·
Tristan Manalac
Deals
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy
The cornerstone of the deal is Ixo-vec, an intravitreal gene therapy currently in Phase III development for wet age-related macular degeneration. Eli Lilly made another foray into genetic medicine in June, picking up Verve Therapeutics for up to $1.3 billion.
October 24, 2025
·
2 min read
·
Heather McKenzie
Drug Development
Verve’s Gene Editor Cuts Cholesterol in First-in-Human HeFH Trial
When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.
November 13, 2023
·
2 min read
·
Tristan Manalac
1 of 28,192
Next
